British Association of Dermatologists' guidelines for the management of squamous cell carcinoma in situ (Bowen's disease) 2014

Authors


  • Funding sources None.
  • Conflicts of interest C.A.M. has acted as an invited speaker for Galderma (specific), Astellas (nonspecific), Almirall (nonspecific) and LEO Pharma (nonspecific); has received sponsorship to attend conferences from LEO Pharma (nonspecific); and has participated in the advisory boards of Almirall, Astellas and LEO Pharma (nonspecific). D.J.E. has participated in the advisory board of, and received travel expenses from LEO Pharma (nonspecific). C.A.M., A.J.B. and D.J.E. are members of the guideline development group.
  • This is an updated guideline prepared for the British Association of Dermatologists (BAD) Clinical Standards Unit, made up of the Therapy & Guidelines (T&G) Subcommittee. Members of the Clinical Standards Unit are J.R. Hughes (Chairman T&G), A. Sahota, A.J. McDonagh, D.A. Buckley, I. Nasr, V.J. Swale, C.E. Duarte Williamson, P.M. McHenry, N.J. Levell, T. Leslie, S. Wagle (British National Formulary), K. Towers (British National Formulary), R. Davis (British Dermatological Nursing Group), S.E. Haveron (BAD Scientific Administrator), L.S. Exton (BAD Information Scientist) and M.F. Mohd Mustapa (BAD Clinical Standards Manager).

  • Guidelines Produced in 1999 by the British Association of Dermatologists; reviewed and updated 2006, 2014.

Ancillary